Cargando…

Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors

Excessive Ca(2+) currents via N-methyl-D-aspartate receptors (NMDARs) have been implicated in many disorders. Uncompetitive NMDAR channel blockers are an emerging class of drugs in clinical use for major depressive disorder (MDD) and other neuropsychiatric diseases. The pharmacological characterizat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bettini, Ezio, Stahl, Stephen M., De Martin, Sara, Mattarei, Andrea, Sgrignani, Jacopo, Carignani, Corrado, Nola, Selena, Locatelli, Patrizia, Pappagallo, Marco, Inturrisi, Charles E., Bifari, Francesco, Cavalli, Andrea, Alimonti, Andrea, Pani, Luca, Fava, Maurizio, Traversa, Sergio, Folli, Franco, Manfredi, Paolo L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414551/
https://www.ncbi.nlm.nih.gov/pubmed/36015145
http://dx.doi.org/10.3390/ph15080997
_version_ 1784776015789162496
author Bettini, Ezio
Stahl, Stephen M.
De Martin, Sara
Mattarei, Andrea
Sgrignani, Jacopo
Carignani, Corrado
Nola, Selena
Locatelli, Patrizia
Pappagallo, Marco
Inturrisi, Charles E.
Bifari, Francesco
Cavalli, Andrea
Alimonti, Andrea
Pani, Luca
Fava, Maurizio
Traversa, Sergio
Folli, Franco
Manfredi, Paolo L.
author_facet Bettini, Ezio
Stahl, Stephen M.
De Martin, Sara
Mattarei, Andrea
Sgrignani, Jacopo
Carignani, Corrado
Nola, Selena
Locatelli, Patrizia
Pappagallo, Marco
Inturrisi, Charles E.
Bifari, Francesco
Cavalli, Andrea
Alimonti, Andrea
Pani, Luca
Fava, Maurizio
Traversa, Sergio
Folli, Franco
Manfredi, Paolo L.
author_sort Bettini, Ezio
collection PubMed
description Excessive Ca(2+) currents via N-methyl-D-aspartate receptors (NMDARs) have been implicated in many disorders. Uncompetitive NMDAR channel blockers are an emerging class of drugs in clinical use for major depressive disorder (MDD) and other neuropsychiatric diseases. The pharmacological characterization of uncompetitive NMDAR blockers in clinical use may improve our understanding of NMDAR function in physiology and pathology. REL-1017 (esmethadone-HCl), a novel uncompetitive NMDAR channel blocker in Phase 3 trials for the treatment of MDD, was characterized together with dextromethorphan, memantine, (±)-ketamine, and MK-801 in cell lines over-expressing NMDAR subtypes using fluorometric imaging plate reader (FLIPR), automated patch-clamp, and manual patch-clamp electrophysiology. In the absence of Mg(2+), NMDAR subtypes NR1-2D were most sensitive to low, sub-μM glutamate concentrations in FLIPR experiments. FLIPR Ca(2+) determination demonstrated low μM affinity of REL-1017 at NMDARs with minimal subtype preference. In automated and manual patch-clamp electrophysiological experiments, REL-1017 exhibited preference for the NR1-2D NMDAR subtype in the presence of 1 mM Mg(2+) and 1 μM L-glutamate. Tau off and trapping characteristics were similar for (±)-ketamine and REL-1017. Results of radioligand binding assays in rat cortical neurons correlated with the estimated affinities obtained in FLIPR assays and in automated and manual patch-clamp assays. In silico studies of NMDARs in closed and open conformation indicate that REL-1017 has a higher preference for docking and undocking the open-channel conformation compared to ketamine. In conclusion, the pharmacological characteristics of REL-1017 at NMDARs, including relatively low affinity at the NMDAR, NR1-2D subtype preference in the presence of 1 mM Mg(2+), tau off and degree of trapping similar to (±)-ketamine, and preferential docking and undocking of the open NMDAR, could all be important variables for understanding the rapid-onset antidepressant effects of REL-1017 without psychotomimetic side effects.
format Online
Article
Text
id pubmed-9414551
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94145512022-08-27 Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors Bettini, Ezio Stahl, Stephen M. De Martin, Sara Mattarei, Andrea Sgrignani, Jacopo Carignani, Corrado Nola, Selena Locatelli, Patrizia Pappagallo, Marco Inturrisi, Charles E. Bifari, Francesco Cavalli, Andrea Alimonti, Andrea Pani, Luca Fava, Maurizio Traversa, Sergio Folli, Franco Manfredi, Paolo L. Pharmaceuticals (Basel) Article Excessive Ca(2+) currents via N-methyl-D-aspartate receptors (NMDARs) have been implicated in many disorders. Uncompetitive NMDAR channel blockers are an emerging class of drugs in clinical use for major depressive disorder (MDD) and other neuropsychiatric diseases. The pharmacological characterization of uncompetitive NMDAR blockers in clinical use may improve our understanding of NMDAR function in physiology and pathology. REL-1017 (esmethadone-HCl), a novel uncompetitive NMDAR channel blocker in Phase 3 trials for the treatment of MDD, was characterized together with dextromethorphan, memantine, (±)-ketamine, and MK-801 in cell lines over-expressing NMDAR subtypes using fluorometric imaging plate reader (FLIPR), automated patch-clamp, and manual patch-clamp electrophysiology. In the absence of Mg(2+), NMDAR subtypes NR1-2D were most sensitive to low, sub-μM glutamate concentrations in FLIPR experiments. FLIPR Ca(2+) determination demonstrated low μM affinity of REL-1017 at NMDARs with minimal subtype preference. In automated and manual patch-clamp electrophysiological experiments, REL-1017 exhibited preference for the NR1-2D NMDAR subtype in the presence of 1 mM Mg(2+) and 1 μM L-glutamate. Tau off and trapping characteristics were similar for (±)-ketamine and REL-1017. Results of radioligand binding assays in rat cortical neurons correlated with the estimated affinities obtained in FLIPR assays and in automated and manual patch-clamp assays. In silico studies of NMDARs in closed and open conformation indicate that REL-1017 has a higher preference for docking and undocking the open-channel conformation compared to ketamine. In conclusion, the pharmacological characteristics of REL-1017 at NMDARs, including relatively low affinity at the NMDAR, NR1-2D subtype preference in the presence of 1 mM Mg(2+), tau off and degree of trapping similar to (±)-ketamine, and preferential docking and undocking of the open NMDAR, could all be important variables for understanding the rapid-onset antidepressant effects of REL-1017 without psychotomimetic side effects. MDPI 2022-08-13 /pmc/articles/PMC9414551/ /pubmed/36015145 http://dx.doi.org/10.3390/ph15080997 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bettini, Ezio
Stahl, Stephen M.
De Martin, Sara
Mattarei, Andrea
Sgrignani, Jacopo
Carignani, Corrado
Nola, Selena
Locatelli, Patrizia
Pappagallo, Marco
Inturrisi, Charles E.
Bifari, Francesco
Cavalli, Andrea
Alimonti, Andrea
Pani, Luca
Fava, Maurizio
Traversa, Sergio
Folli, Franco
Manfredi, Paolo L.
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
title Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
title_full Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
title_fullStr Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
title_full_unstemmed Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
title_short Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
title_sort pharmacological comparative characterization of rel-1017 (esmethadone-hcl) and other nmdar channel blockers in human heterodimeric n-methyl-d-aspartate receptors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414551/
https://www.ncbi.nlm.nih.gov/pubmed/36015145
http://dx.doi.org/10.3390/ph15080997
work_keys_str_mv AT bettiniezio pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT stahlstephenm pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT demartinsara pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT mattareiandrea pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT sgrignanijacopo pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT carignanicorrado pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT nolaselena pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT locatellipatrizia pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT pappagallomarco pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT inturrisicharlese pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT bifarifrancesco pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT cavalliandrea pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT alimontiandrea pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT paniluca pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT favamaurizio pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT traversasergio pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT follifranco pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors
AT manfredipaolol pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors